Moreover, our results demonstrated that in the CR phase, the expression level of MAP1LC3B, ATG5, ATG10, RB1CC1, and AMBRA1 genes was significantly reduced (0.71, 0.73, 0.5, 0.72, and 0.75‐folds, respectively) as compared to newly diagnosed AML patients (p = 0.006, 0.003, 0.0002, 0.006, and 0.004, respectively) (Figure 2). This evidence concerns the gene MAP1LC3B and acute myeloid leukemia.